[A18-38] Ocrelizumab (multiple sclerosis) - Addendum to Commission A18-06

Last updated 02.08.2018

Project no.:
A18-38

Commission:
Commission awarded on 12.06.2018 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Head and nerves

Indication:

Adults with active relapsing multiple sclerosis (RMS) or with early primary progressive multiple sclerosis (PPMS)

Result of dossier assessment:

Active RMS: proof of considerable (< 40 years) or minor (≥ 40 years) added benefit; highly active RMS: added benefit not proven. PPMS: indication of lesser benefit than appropriate comparator therapy

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2018-08-02 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.